title: Bone Morphogenetic Proteins in Lumbar Arthrodesis: What Is All the Debate About? Commentary on an article by Daniel C. Beachler, PhD, MHS, et al.: "Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare Database".
authors.forename: Kern
authors.initials: K
authors.lastname: Singh
authors.forename: Dustin H
authors.initials: DH
authors.lastname: Massel
authors.forename: Benjamin C
authors.initials: BC
authors.lastname: Mayo
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Bohl
authors.forename: William W
authors.initials: WW
authors.lastname: Long
authors.affiliation: Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois.
authors.forename: Krishna D
authors.initials: KD
authors.lastname: Modi
mesh_terms: D001174:Arthrodesis; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use; D019485:Bone Morphogenetic Proteins; D015331:Cohort Studies; D006801:Humans; D008159:Lumbar Vertebrae; D006278:Medicare; D009369:Neoplasms / Q000139:chemically induced; D011994:Recombinant Proteins; D013123:Spinal Fusion; D016212:Transforming Growth Factor beta / Q000627:therapeutic use
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta